Alzheimer’s Disease Data Initiative launches new AD Workbench to foster greater global research innovation and accelerate breakthroughs in Alzheimer’s disease and related dementias
18 November 2020
Platform gives scientists open access to more data and new tools
SEATTLE (November 17, 2020) – Launching today is the Alzheimer’s Disease Data Initiative (ADDI) and its Alzheimer’s disease (AD) Workbench, a cloud-based platform for scientists to accelerate discoveries and innovations for AD and related dementias. ADDI is a new global effort that aims to advance AD innovation by connecting researchers with the data needed to generate insights and inform the development of improved treatments and diagnostic tools. ADDI, a 501(c)(3) medical research organization, was created by a coalition of partners to increase sharing of dementia-related data among researchers and provide new ways to experiment with the most trusted datasets.
For decades, scientists have made limited progress in Alzheimer’s research and therapeutics, even though Alzheimer’s is a leading cause of death around the world with care estimated to cost more than $1 trillion annually. Now more than ever, greater data sharing is needed to spark innovative discoveries in AD research. Advancement is possible—limited access to data should not be a barrier.
The idea for ADDI was initiated in 2018, after Bill Gates brought together a coalition of partners interested in improving AD and related dementias data sharing with the aim of moving innovation further and faster toward better treatments and diagnostic tools.
“The need for new and more effective treatments for Alzheimer’s disease has never been greater. A better understanding of the disease will help us detect and diagnose it earlier. It should be easier for people to find, enroll and stay in clinical trials, and we must accelerate the pace of discovery and innovation. Data can play a critical role in breakthroughs,” said Bill Gates. “Data is a tremendously powerful tool that can be better harnessed to understand and reduce the impact of AD. It’s what the AD Workbench is designed to do.”
The AD Workbench will facilitate interoperability across data platforms and enable researchers to work with multiple datasets. With a federated model of data sharing, the AD Workbench allows permissioned researchers to import their datasets, access, and transfer data from other platforms. It also allows them to work securely with anonymized datasets that are unable to be transferred due to data privacy, regulation and local laws. Within the platform, users have a personalized workspace where they can ensure quality control, harmonize data, and analyze data within the platform. Soon the AD Workbench will provide researchers and data scientists with the ability to share code and crowdsource ideas.
Rafael Jimenez, Head of Research Informatics at Alzheimer’s Research UK, said:
“Alzheimer’s Research UK is proud to be a partner in this new initiative led by Gates Ventures, and our Early Detection of Neurodegenerative diseases (EDoN) initiative will be one of the first to use this pioneering resource.
“Early detection is a critical step for tackling the diseases that cause dementia. The EDoN initiative is developing a digital device, like a mobile app or wearable, that can detect diseases that cause dementia 10-15 years earlier than we can today.
“The device will pick up subtle physiological and behavioural changes such as the way we move, how we communicate, our sleep patterns or heart rate. We will validate these changes with data from brain scans, blood and spinal fluid tests collected from clinical research studies involving people with diseases like Alzheimer’s. The digital and clinical data we will be used to train algorithms to identify the early signs of a disease. The more data we can feed into these machine learning algorithms, the better our tools will be.
“ADDI puts clinical data in one place and harmonises it so that we can combine, compare and analyse it to power research that would not have been possible before. EDoN is a great example of how this new initiative will help to reduce the impact of dementia and transform millions of lives.”
Tetsu Maruyama, Executive Director of ADDI, said
“There are no limits to the innovation that can arise from researchers working together with more data than ever before,” “That’s what makes the Workbench so exciting – and it’s just the beginning. The Workbench will continue to evolve with input and data from the research community, allowing scientists to work with new tools and more data.”
The Workbench will increase access to many types of data that will both speed our basic understanding of AD and related dementias and progress toward new treatments by:
- Allowing scientists to combine data from multiple studies to strengthen understanding beyond what could be learned from a single study;
- Enabling researchers to revisit existing datasets with new analytical methods and technologies; and
- Accelerating future research by breaking down traditional research barriers.
“There is tremendous power in data sharing and the ability to harmonize data across multiple groups,” said Dr. Reisa Sperling, Director, Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital. “The AD Workbench will make it easier to access and explore data in new ways and expand collaboration opportunities.”
ADDI will foster an environment that supports and facilitates researchers’ abilities to share data by providing resources. In addition to the AD Workbench, ADDI has collated existing tools and created new tools that will help researchers navigate regulatory frameworks and policies that are often barriers to data sharing. ADDI will also provide grants to fund researchers and organizations that seek to expand data access and sharing using the AD Workbench. Increasing access to the best and most trusted datasets is one of the most effective ways to accelerate progress toward more effective treatments, and the diagnostics that can help physicians and people with dementia. Together, these breakthroughs will drastically reduce the impact of AD on patients, their families, and the healthcare system.
For more information please visit: